This event will underline the key role of the fight against AMR to ensure we deliver on SDG 3, but also SDGs 1, 2 and 8, and focus specifically on how the life science industry could contribute. What actions have already been undertaken, where does industry have the most added-value, where there is space and need for more collaboration to succeed?
Experts from diverse life sciences companies will share their perspective on how their business can contribute specifically, what are their respective strengths and where gaps remain. In addition, global health experts will offer their recommendations to set aspirational goals for the industry and incentives further collaborations with governments.
The AMR Industry Alliance brings together over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations, to drive and measure the life-sciences’ industry progress to curb antimicrobial resistance. The Alliance has partnered with SustainAbility to deliver its first progress report, which compiles the results of how members of are meeting the Alliance’s goals in four different areas: Research and Science, Access, Appropriate Use, and Environment. It is the first attempt to aggregate and report the diverse industry activities relating the development of AMR. This first report will be launched at this event and will serve to benchmark progress, set targets for the future and identify gaps where further efforts may be required.
A light lunch will be served before the event at 12:00-12:30.
For more information, view the Progress Report, press release and case studies.
Programme and biographies of speakers